Key result
Fabry disease iPSC-CMs show increased AF vulnerability and altered electrophysiology vs. wild-type in silico.
Answers are grounded in this paper and cite their sources.
BACKGROUND: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by α-Gal A (α-galactosidase A) deficiency, resulting in multiorgan accumulation of sphingolipid, namely globotriaosylceramide. This triggers ventricular myocardial hypertrophy, fibrosis, and inflammation, driving arrhythmia and sudden death. Atrial fibrillation is common, yet the cellular mechanisms accounting for this are unknown. METHODS: iPSC-CMs. RESULTS: iPSC-CMs demonstrated a more positive diastolic membrane potential, faster action potential upstroke velocity, greater incidence of delayed afterdepolarizations, greater contraction force, and alterations in calcium handling compared with wild-type iPSC-CMs. Simulations with these changes in the in silico models resulted in similar P-wave morphology changes to those seen in early FD cardiomyopathy and increased atrial fibrillation vulnerability. CONCLUSIONS: These findings provide novel insights into underpinning mechanisms for atrial arrhythmia and a rationale for early P-wave changes in FD. These may be targeted to develop therapeutic strategies to reduce the arrhythmic burden in FD.
No takes yet. Share an insight, caveat, or question.
Roy et al. (2025) studied Fabry disease. Fabry disease vs. wild-type iPSC-CMs was evaluated on electrophysiological properties and P-wave morphology. Fabry disease iPSC-CMs demonstrated altered electrophysiology and increased atrial fibrillation vulnerability in silico compared with wild-type cells.
Synapse has enriched 10 related papers. Consider them for comparative context: